Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Maze Therapeutics Inc (MAZE)

Maze Therapeutics Inc (MAZE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,510,159
  • Shares Outstanding, K 49,709
  • Annual Sales, $ 167,500 K
  • Annual Income, $ 52,230 K
  • EBIT $ -135 M
  • EBITDA $ -131 M
  • 60-Month Beta 4.47
  • Price/Sales N/A
  • Price/Cash Flow 207.13
  • Price/Book 4.30

Options Overview Details

View History
  • Implied Volatility 79.94% (+4.72%)
  • Historical Volatility 134.73%
  • IV Percentile 15%
  • IV Rank 5.93%
  • IV High 228.70% on 03/10/26
  • IV Low 70.56% on 12/22/25
  • Expected Move (DTE 18) 3.40 (11.19%)
  • Put/Call Vol Ratio 0.22
  • Today's Volume 116
  • Volume Avg (30-Day) 449
  • Put/Call OI Ratio 0.36
  • Today's Open Interest 5,865
  • Open Int (30-Day) 3,066
  • Expected Range 26.98 to 33.78

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.45
  • Number of Estimates 5
  • High Estimate -0.32
  • Low Estimate -0.65
  • Prior Year -1.15
  • Growth Rate Est. (year over year) +60.87%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.16 +4.19%
on 03/27/26
53.65 -43.37%
on 03/16/26
-15.21 (-33.36%)
since 02/27/26
3-Month
29.16 +4.19%
on 03/27/26
53.65 -43.37%
on 03/16/26
-11.72 (-27.84%)
since 12/26/25
52-Week
6.71 +352.76%
on 04/09/25
53.65 -43.37%
on 03/16/26
+19.11 (+169.57%)
since 03/27/25

Most Recent Stories

More News
U.S. Jobs Figures Issued in Short Week

MondayFeatured Earnings Maze Therpautics (NASDAQ:MAZE) (Q4) EPS for loss of 73 cents, compared ...

AYI : 269.69 (-0.24%)
MKC : 53.07 (+2.89%)
FDS : 198.33 (+1.05%)
MSM : 90.30 (+0.92%)
CAG : 15.62 (+2.76%)
NKE : 51.37 (-1.34%)
PRGS : 27.67 (-5.14%)
POET : 5.19 (-5.46%)
LW : 41.60 (+1.89%)
ANGO : 10.90 (-3.28%)
MAZE : 30.38 (-4.19%)
LNN : 117.72 (-2.32%)
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease

– At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients, 50% of the patients achieved a greater than 30% reduction in uACR, and treatment was well-tolerated...

MAZE : 30.38 (-4.19%)
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference...

MAZE : 30.38 (-4.19%)
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease

– At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients, 50% of the patients achieved a greater than 30% reduction in uACR, and treatment was well-tolerated...

MAZE : 30.38 (-4.19%)
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference...

MAZE : 30.38 (-4.19%)
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients...

MAZE : 30.38 (-4.19%)
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients...

MAZE : 30.38 (-4.19%)
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients...

MAZE : 30.38 (-4.19%)
Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected to initiate...

MAZE : 30.38 (-4.19%)
Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients...

MAZE : 30.38 (-4.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

Relative Strength is below 30%. The market is in oversold territory. Watch for a potential trend reversal.

See More Share

Business Summary

Maze Therapeutics Inc. is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases. Maze Therapeutics Inc. is based in SOUTH SAN FRANCISCO, Calif....

See More

Key Turning Points

3rd Resistance Point 35.16
2nd Resistance Point 33.71
1st Resistance Point 32.05
Last Price 30.38
1st Support Level 28.94
2nd Support Level 27.49
3rd Support Level 25.83

See More

52-Week High 53.65
Fibonacci 61.8% 35.72
Last Price 30.38
Fibonacci 50% 30.18
Fibonacci 38.2% 24.64
52-Week Low 6.71

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.